Atoltivimab |
Catalog No.GC72370 |
Atoltivimab (REGN3470), or maftivimab/odesivimab (Inmazeb) is the first Food and agent Administration (FDA)-approved monoclonal antibody to target Zaire ebolavirus (EBOVs) infection.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2135632-29-8
Sample solution is provided at 25 µL, 10mM.
Atoltivimab (REGN3470), or maftivimab/odesivimab (Inmazeb) is the first Food and agent Administration (FDA)-approved monoclonal antibody to target Zaire ebolavirus (EBOVs) infection.
References:
[1]. Saxena D, et al. Atoltivimab/maftivimab/odesivimab (Inmazeb) combination to treat infection caused by Zaire ebolavirus. Drugs Today (Barc). 2021 Aug;57(8):483-490.
Review for Atoltivimab
Average Rating: 5
(Based on Reviews and 30 reference(s) in Google Scholar.)Review for Atoltivimab
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *